Why carry out this study?

The risk of nonvalvular atrial fibrillation (NVAF) is increased among individuals with obesity and diabetes.

Obesity is a worldwide public health crisis that increases the risk of comorbidities and contributes substantially to healthcare expenditures.

What did the study ask?

This real-world study evaluated and compared healthcare resource utilization (HRU) and costs of rivaroxaban and warfarin in patients with NVAF, obesity, and diabetes.

What were the study outcomes?

All-cause HRU rate ratios were significantly reduced with rivaroxaban versus warfarin in all healthcare settings evaluated, except emergency room visits.

NVAF-related HRU was significantly lower for rivaroxaban versus warfarin in all healthcare settings.

Rivaroxaban was associated with reductions in all-cause and NVAF-related costs.

What was learned from the study?

HRU and costs were lower with rivaroxaban compared with warfarin in patients with NVAF and concurrent obesity and diabetes.

Treatment differences in HRU and costs were mainly observed for hospital inpatient and outpatient visits and physician office visits, supporting the need for fewer healthcare interactions during rivaroxaban therapy compared with warfarin therapy.